As mentioned above, c-Met is aberrantly activated by gene amplification, overexpression, mutation, binding to other ligands, autocrine signaling or abnormally high HGF levels in cancer
Adjusting the dose, switching peptides, or stopping treatment are valid responses based on clinical judgment
April 2026 Category 2 Update On April 15, 2026, the FDA confirmed removal of injectable GHK-Cu from Category 2 because the original nominations were withdrawn
The BDNF Isoforms Positively and Negatively Contribute to Maintenance of Brain Homeostasis One of the most important features of BDNF synthesis is the elaboration of several functionally active isoforms, such as pro-BDNF, m-BDNF, pro-domain sequence, and Val66Met polymorphic pro-domain variant
Multifunctional incretin peptides in therapies for type 2 diabetes, obesity and associated co-morbidities